Investigator grants to deliver more targeted healthcare miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Sequana Medical NV: Sequana Medical s results from RED DESERT alfapump DSR study presented as one of the Highlights at Heart Failure 2021 Online Congress
the Company or Sequana Medical
), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of
alfapump DSR (Direct Sodium Removal) which were presented at the Heart Failure 2021 Online Congress as part of the Late Breaking Science Results were also selected for the congress Highlights session, held virtually on 1 July 2021.
Dr
,
, at the Heart Failure 2021
Online
a
improvement in diuretic response.
Ghent, BELGIUM - 9 June 2021 - Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease
Investegate announcements from Sequana Medical NV, Results from Sequana Medical’s RED DESERT alfapump DSR® study selected for presentation at the Heart Failure 2021 Online Congress
Tampa Bay area doctors share medical advancements in use of stem cells
WFTS
and last updated 2021-06-09 12:07:33-04
The medical community is shining a light on stem cells and their use to treat a variety of conditions. Doctors in the Tampa Bay area are sharing the innovative ways stem cell treatments could dramatically change lives.
âStem cells are the building blocks of life,â said Dr. Leslie Miller.
Through the years, research continues into the use of stem cells.
âStem cells are actually what we call it as pluripotent cells in the body, which itâs basically kind of cells which can actually regenerate multiple times. They donât even die, and they can actually differentiate into various forms of cells in your body,â said Dr. Deepak Chellapandian.